Alpelisib is an oral selective PIK3α isoform inhibitor, exhibiting dose-dependent antitumor activity in preclinical models, including tumor xenograft models, with more pronounced activity against PIK3CA-mutated tumors [315]. Here, PIK3CA is linked to neoplasm.